Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829582 | 0.98 | CYP17A1 (0.39) | GAAEPHX1CYP17A1NFKB1NFKB2 | |
| SCHEMBL573575 | 0.94 | NFKB1 (0.39) | GAAEPHX1CYP17A1NFKB1NFKB2 | |
| SCHEMBL1656241 | 0.90 | NFKB1 (0.41) | GAACYP17A1NFKB1NFKB2RELA | |
| SCHEMBL1551115 | 0.79 | ALDH1A1 (0.40) | GAAEPHX1NFKB1NFKB2RELA | |
| SCHEMBL28960308 | 0.79 | BTK (0.38) | GAAEPHX1NFKB1NFKB2RELA | |
| SCHEMBL2397844 | 0.79 | TSHR (0.44) | ALDH1A1 | |
| SCHEMBL28976941 | 0.77 | TSHR (0.35) | GAANFKB1NFKB2RELACA2 | |
| SCHEMBL27882879 | 0.76 | TSHR (0.46) | ALDH1A1KMT2A | |
| SCHEMBL28167286 | 0.73 | GAA (0.38) | GAANFKB1NFKB2RELACA2 | |
| SCHEMBL28466003 | 0.73 | CYP17A1 (0.37) | GAACYP17A1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| CN-105142673-B | Novel cyclohexyl and quininuclidinyl carbamate derivatives with beta 2-adrenergic activator and M3 muscarinic antagonists activity | 阿尔米雷尔有限公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-103003281-A | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | disclosed |
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| CN-101263134-A | Imidazole-4-carboxamide derivatives as CB modulators | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| EP-1940820-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031721-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | CNR2, CNR1, FAAH | GAA 1701/4885EPHX1 1321/4885CYP17A1 1005/4885 |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | ITGB4, ITGA4, ITGB5 | GAA 2720/4885EPHX1 1221/4885CYP17A1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.